Led · Equity · Jul 2026

The article reports that Caravela entered Aviva’s US$18 million financing round as a participating investor. Beyond its participation in this transaction, the article does not provide information on Caravela’s core products, services, founding year, location, or operating metrics. The report contains no statements about Caravela’s future plans or financial position. No revenue, user, or other performance metrics for Caravela are provided in the coverage.

Participated · Equity · Feb 2026

Tembo Money offers a mobile platform that integrates savings products such as Lifetime ISAs, Cash ISAs, and Fixed Rate ISAs with a free digital mortgage advice service. Its newest product, HomeSaver, links saving and borrowing by providing a 5.24% savings rate to customers who later use Tembo for their home purchase or remortgage. The app continues supporting users post-purchase by tracking their mortgage in real time and surfacing the best available remortgage rates from both their existing lender and the broader market. Tembo’s leadership claims the company is on track to capture 20% of the UK first-time buyer market within two years, highlighting strong growth ambitions. The fresh capital will fuel further expansion of its app functionality and the development of a fully end-to-end home-buying platform. No revenue or user numbers were disclosed in the article. The company is led by co-founder and CEO Richard Dana.

Participated · Equity · Nov 2025

FNZ delivers an end-to-end wealth-management platform that combines custody, trading, and digital advice tools for banks, insurers, asset managers, and advisers. Its technology handles $2.1 trillion of assets, a five-fold increase since 2020, underscoring rapid adoption across North America, Europe, Asia-Pacific, and Africa. The company has recently deepened its technology roadmap through a strategic partnership with Microsoft and the rollout of proprietary AI products aimed at boosting advisor productivity. FNZ is also focused on operational excellence, having completed a Section 166 review in the UK after upgrading its governance, risk, and delivery frameworks. Fresh capital will be funneled into product development, talent acquisition, and continued global expansion while bolstering the firm’s balance sheet. Executives highlight a renewed emphasis on client delivery, operational discipline, and profitable growth as the company scales its wealth-management modernization efforts worldwide.

Participated · Seed · Aug 2025

Meshed offers an AI-native digital broking platform that uses AI-powered browser and voice agents to handle quote gathering, insurer chasing, and policy administration for SMEs. The company is rebuilding the insurance broking stack from the ground up—data infrastructure, schemas, and integrations—to reduce costs and improve coverage accuracy. Its agents aim to shorten quoting times dramatically (from around one hour to nine minutes) and deliver real-time policy updates to help businesses avoid underinsurance. Meshed has secured regulatory approval as an Appointed Representative from the UK Financial Conduct Authority and has agreements with 51 insurers. The founding team is composed of seasoned insurance and technology operators focused on replacing legacy software and manual processes. The company raised funding to accelerate product development and go-to-market for commercial SME insurance.

Participated · Series E · Jan 2025

Owlstone Medical is building a breathalyser-style diagnostic platform that captures and analyses volatile organic compounds (VOCs) in exhaled breath to identify disease-specific biomarkers. Its core Breath Biopsy® platform is powered by the ReCIVA® Breath Sampler and supported by proprietary FAIMS microchip chemical sensor technology and EVOC® probes. The company’s vision is to save 100,000 lives and cut healthcare costs by $1.5 billion through earlier, more precise detection and treatment. Owlstone’s technology is being expanded to cover respiratory and liver diseases, digestive health disorders, and, most prominently, cancer. A newly awarded ARPA-H contract of up to $49.1 million will finance development of a synthetic-sensor multi-cancer early-detection (MCED) test that can identify more than 30 solid tumours at Stage I using breath and urine samples. The program will deliver single-use inhalers containing pan-cancer and tumour-specific sensors, with results uploaded directly to electronic health records for rapid clinical review. Partnerships with MIT, Boston University, Georgia Tech Research Corporation, Qurin B.V., and Planned Systems International will help advance this low-cost, home-usable diagnostic toward commercial deployment.